Biogen Inc.

NasdaqGS:BIIB Stok Raporu

Piyasa değeri: US$27.9b

Biogen Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Biogen kazanç ve gelirin sırasıyla yıllık 13.9% ve 2.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 14.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 12.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

13.9%

Kazanç büyüme oranı

14.43%

EPS büyüme oranı

Biotechs kazanç büyümesi24.1%
Gelir büyüme oranı2.4%
Gelecekteki özkaynak getirisi12.51%
Analist kapsamı

Good

Son güncelleme04 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential

Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.

BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism

Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.

Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease

Apr 06

BIIB: 2026 Clinical Outcomes Will Likely Challenge Recent Neuroscience Optimism

The analyst price target for Biogen has been adjusted slightly to $150. This reflects recent model updates that incorporate a modestly higher discount rate, slightly lower revenue growth assumptions, a small uptick in expected profit margins, and Street research focusing on price target changes and evolving views on the company's pipeline and neurology portfolio.

Biogen Inc. (BIIB): The "Post-MS" Pivot and the Alzheimer’s Momentum

Biogen Inc. (BIIB) is navigating a high-stakes transition year in 2026, closing the March 31, 2026, session at $178.98 USD on the NASDAQ.

BIIB: 2026 Clinical Readouts Will Likely Undermine Recent Pipeline Optimism

Analysts have nudged Biogen's fair value estimate higher to $151.48 from $147.47, reflecting a series of recent price target increases across the Street and ongoing reassessments of the company's pipeline and commercial outlook. Analyst Commentary Recent Street research around Biogen points to a mixed setup, with several firms adjusting price targets and ratings as they reassess the pipeline, commercial execution, and sector positioning.

BIIB: 2026 Clinical Readouts And Easing Policy Risks Will Drive Upside

The analyst fair value estimate for Biogen has increased by about $16 to $205.67 as analysts factor in recent price target revisions and updated views on the pipeline and commercial outlook. Analyst Commentary Recent research updates on Biogen cluster around revisions to price targets, refreshed models on the pipeline, and differing expectations for execution in 2026 and beyond.

BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk

The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.

There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

Feb 13
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

BIIB: 2026 Clinical Readouts And Pipeline Execution Will Drive Upside Potential

Analysts have nudged their price targets on Biogen higher, with our fair value estimate rising to about $255.45 from $247.88 as they update models for revenue growth, margins, and a modestly richer future P/E multiple following a series of mixed but generally upward target revisions across the Street. Analyst Commentary Recent research on Biogen has been mixed, but the pricing and modeling changes skew toward a constructive tone.

BIIB: 2026 Clinical Readouts Will Test Lofty Pipeline Expectations

Analysts have raised their Biogen fair value estimate from $128.00 to $143.00, citing refreshed models and higher Street price targets as they incorporate updated views on the pipeline, sector conditions, and 2026 catalysts. Analyst Commentary Street research around Biogen points to a generally more constructive view on the shares, with several firms lifting price targets into a range between about $180 and $225.

BIIB: Easing Policy Shifts And 2026 Pipeline Readouts Will Shape Outlook

Narrative Update: Biogen (BIIB) Biogen's fair value estimate has moved from about $181 to around $190 as analysts lift price targets into the $180 to $225 range and highlight updated models, slightly better margin and growth assumptions, and potential pipeline and sector catalysts through 2026. Analyst Commentary Recent research updates on Biogen cluster around a tighter valuation band in the high US$100s to low US$200s, with most firms revisiting their models and assumptions for 2025 to 2026.

BIIB: Easing Policy Overhangs And Alzheimer’s Data Will Shape Risk Reward Balance

Analysts have modestly raised their price target on Biogen, now implying upside in line with a slightly higher fair value of approximately $181, citing easing policy overhangs and a partial rerating of large-cap biopharma as investor focus shifts back to fundamentals. Analyst Commentary Street research on Biogen has turned incrementally more constructive, with several firms lifting price targets as macro and policy risks appear less threatening to the sector.

BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead

Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.

BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead

Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.

BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025

Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.

Easing Policy Risks And New Therapy Launches Will Drive Shares Higher

Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly

Jun 17
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Apr 25

Biogen: Balancing Risks And Opportunities

Mar 27

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Feb 15

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:BIIB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202810,6082,1342,4063,32217
12/31/202710,3171,9292,5742,63622
12/31/202610,0121,1402,6971,84222
3/31/20269,9371,3722,3162,591N/A
12/31/20259,8911,2931,9692,205N/A
9/30/202510,0661,6092,2622,454N/A
6/30/20259,9971,5311,8322,117N/A
3/31/20259,8161,4792,3842,582N/A
12/31/20249,6761,6322,6042,876N/A
9/30/20249,6081,6151,8572,127N/A
6/30/20249,6721,1591,5711,784N/A
3/31/20249,6631,1671,2841,645N/A
12/31/20239,8361,1611,2361,547N/A
9/30/20239,9931,4621,0261,360N/A
6/30/20239,9722,6651,1231,428N/A
3/31/202310,1053,1311,4211,678N/A
12/31/202210,1733,0471,1411,384N/A
9/30/202210,3632,8652,1732,398N/A
6/30/202210,6342,0592,3152,542N/A
3/31/202210,8201,4502,7733,033N/A
12/31/202110,9821,5563,3453,640N/A
9/30/202111,1011,5462,1072,435N/A
6/30/202111,6981,9182,4612,810N/A
3/31/202112,6043,0123,1493,532N/A
12/31/202013,4454,0013,6784,230N/A
9/30/202014,2635,0825,8416,557N/A
6/30/202014,4875,9276,3497,071N/A
3/31/202014,4225,8796,2827,086N/A
12/31/201914,3785,889N/A7,079N/A
9/30/201914,2335,396N/A7,014N/A
6/30/201914,0725,294N/A7,055N/A
3/31/201913,8124,667N/A6,190N/A
12/31/201813,4534,431N/A6,188N/A
9/30/201813,2343,187N/A5,811N/A
6/30/201812,8722,968N/A5,703N/A
3/31/201812,5942,964N/A5,773N/A
12/31/201712,2742,539N/A4,551N/A
9/30/201711,8393,486N/A4,615N/A
6/30/201711,7173,293N/A3,978N/A
3/31/201711,5333,480N/A3,807N/A
12/31/201611,4493,703N/A4,587N/A
9/30/201611,4163,885N/A4,046N/A
6/30/201611,2383,818N/A3,950N/A
3/31/201610,9363,695N/A3,999N/A
12/31/201510,7643,547N/A3,919N/A
9/30/201510,5653,599N/A3,609N/A
6/30/201510,2993,490N/A3,627N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BIIB 'nin tahmini kazanç büyümesi (yıllık 13.9% ) tasarruf oranının ( 3.5% ) üzerindedir.

Kazançlar ve Piyasa: BIIB şirketinin kazançlarının (yıllık 13.9% ) US pazarından (yıllık 16.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: BIIB şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: BIIB şirketinin gelirinin (yıllık 2.4% ) US pazarından (yıllık 11.3% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BIIB şirketinin gelirinin (yıllık 2.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BIIB 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 12.5 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/06 03:17
Gün Sonu Hisse Fiyatı2026/05/06 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Biogen Inc. 58 Bu analistlerden 22, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
David ToungArgus Research Company
Brian SkorneyBaird
Emily FieldBarclays